

Does early antibiotic therapy in neonatal sepsis (proven or presumed) negatively impact enteral feeding and neonatal hyperbilirubinaemia?

Authors: Daniel Ng, A/Prof Wei Qi Fan



Background, Aims & Objectives, Methods

Background

- Empirical antibiotic therapy is frequently observed in preterm infant care for the treatment of early-onset sepsis (EOS) (onset at ≤ 72 hours of life).
- Of major concern are its deleterious effects on the gut microbiome which may predispose the infant towards hyperbilirubinaemia and feeding intolerance (FI).
- Current literature exploring the effects of early antibiotic therapy on hyperbilirubinaemia and FI among preterm infants is scarce.

Aims & Objectives

To examine the effects of early antibiotic therapy on the development of hyperbilirubinaemia and FI among preterm infants with proven or presumed EOS.

Methods

Design: Retrospective analysis comparing hyperbilirubinaemia, FI and length of stay (LOS) between infants on EOS antibiotic therapy (ABX) (n = 357) to infants not requiring antibiotic therapy (No ABX) (n = 289).

Participants: Preterm infants (<37 weeks) admitted to The Northern Hospital's Special Care Nursery (SCN) between January 2016 to December 2019.

Statistical Analysis: Data analysis was performed with IBM SPSS Statistics version 26. Non-parametric comparisons were made using Chi-square/Fisher's Exact tests for categorical outcomes, Mann-Whitney rank-sum/Kruskal-Wallis H tests for continuous outcomes. Multivariate logistic and Cox regression analyses were used to account for confounding effects.


Does early antibiotic therapy in neonatal sepsis (proven or presumed) negatively impact enteral feeding and neonatal hyperbilirubinaemia?

Authors: Daniel Ng, A/Prof Wei Qi Fan




Results & Discussion

• **Fig 1:** Infants on antibiotic therapy (ABX) and prolonged therapy (ABX ≥ 5 days) had significantly higher rates of hyperbilirubinaemia and FI than the control group (No ABX).



• **Fig 2:** Infants on antibiotic therapy (ABX) and prolonged therapy (ABX ≥ 5 days) had a significantly longer time to commence enteral feeds (hours) and SCN LOS (days) compared to the control group (No ABX).




Does early antibiotic therapy in neonatal sepsis (proven or presumed) negatively impact enteral feeding and neonatal hyperbilirubinaemia?

Authors: Daniel Ng, A/Prof Wei Qi Fan

Results & Discussion, Conclusion

- Fig 3:** Infants on antibiotic therapy (ABX) and prolonged therapy (ABX ≥ 5 days) had a significantly delayed time to reach full enteral feeds (total fluid intake ≥ 150ml/kg/day).



- Table 1:** On accounting for confounders, antibiotic therapy use (ABX) and prolonged therapy (ABX ≥ 5 days) significantly increased the odds of hyperbilirubinaemia, FI and SCN LOS.

Multivariate regression analysis for infants on antibiotic therapy compared to the control group (n = 646), OR = odds ratio, HR = hazards ratio, CI = confidence interval.			
Outcome	Ratio	95% CI	P-value
Neonatal hyperbilirubinaemia			
Use of antibiotic therapy	OR: 2.48	1.23 - 4.98	0.011
ABX ≥ 5 days	OR: 2.94	1.23 - 7.06	0.016
Feeding intolerance			
Use of antibiotic therapy	OR: 1.48	0.89 - 2.45	0.130
ABX ≥ 5 days	OR: 1.32	0.60 - 2.94	0.491
Time to commence enteral feeds			
Use of antibiotic therapy	OR: 6.51	3.30 - 12.87	<0.001
ABX ≥ 5 days	OR: 9.55	4.47 - 20.38	<0.001
Time to reach full enteral feeds			
Use of antibiotic therapy	HR: 0.824	0.684 - 0.993	<0.001
ABX ≥ 5 days	HR: 0.738	0.545 - 0.998	0.048
Length of stay			
Use of antibiotic therapy	OR: 1.21	1.07 - 1.36	0.003
ABX ≥ 5 days	OR: 1.33	1.12 - 1.58	0.001

Conclusion

Prolonged antibiotic therapy in preterm infants with early-onset sepsis negatively impacts on enteral feeding, neonatal hyperbilirubinaemia & LOS.